Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07424508

Movement State-dependent Adaptive DBS for PD

This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCSF

San Francisco, California, 94134, United States

About this study

This study will allow the investigators to evaluate the efficacy of a movement state-dependent adaptive deep brain stimulation paradigm to treat gait dysfunction in individuals with Parkinson's disease (PD).

While current DBS therapy improves the appendicular symptoms of PD, such as tremor and bradykinesia, it is less effective for advanced gait symptoms, which manifest as hypokinetic gait patterns, increased gait variability, asymmetry, and disturbed balance. These symptoms are debilitating and represent a major source of morbidity for patients with PD. Studies have suggested that while conventional high-frequency stimulation settings are good at treating appendicular symptoms, they may not be as effective for axial symptoms such as gait disorders. Modulating stimulation parameters, by using lower frequencies, for instance, has been shown to improve gait kinematics such as symmetry and rhythmicity. However, these settings are less effective for other symptoms and therefore come at the expense of appendicular symptom control. The overall objective of this study is to identify personalized electrophysiological signatures of movement state and gait-optimized stimulation parameters in PD patients to enable adaptive control algorithms that automatically switch from identified 'gait-optimized' settings during walking to 'other PD symptom-optimized' settings during non-walking.

This is a small, double-blinded trial, six patients with idiopathic PD and motor fluctuations who have already been implanted with the RC+S devices. The investigators will compare the overall efficacy of closed-loop (adaptive DBS) and open-loop (continuous clinical DBS) paradigms in terms of behavioral performance improvements. During this chronic movement state-dependent adaptive DBS phase, adaptive DBS and open-loop stimulation settings will be randomized for 7-day periods, and motor and gait-related measurements will be obtained from wearable devices that track movement kinematics. Patients will participate in daily, if possible, motor and gait tasks at home and are asked to fill out motor diary questionnaires to share their feedback from both motor and non-motor perspectives.

The investigators expect to successfully develop a prototype movement state-dependent adaptive DBS algorithm. They hypothesize that the embedded closed-loop, movement state-dependent adaptive DBS paradigm will improve gait function compared to the conventional open-loop approach, in which stimulation parameters remain constant, while maintaining the standard therapeutic benefits of DBS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to give informed consent for the study
  • Subjects implanted with Summit RC+S investigational DBS system.
  • Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA)
  • Signed informed consent
  • Age 21-75
  • Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater
  • Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist.
  • UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management
  • Patients with gait impairments: slowed gait, shuffling steps, postural instability, or freezing of gait off medication.

Exclusion criteria

  • Inability to comply with study procedures
  • Patients who cannot walk (wheelchair bound)

Treatment and study plan

Summit RC+S

Device

Participants receive gait-optimized stimulation settings while walking and Parkinson's disease symptom-optimized settings during non-walking periods.

Primary outcomes

  1. Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scores

    Time frame: after each 7 day block

    Change in Mini-BESTest scores, which is a clinical balance evaluations systems test. The score range is 0-2 with higher scores indicating higher levels of physical functioning.

  2. Change in Gait

    Time frame: 14 day long-term testing period

    Change in gait measurements using the wearable devices (i.e., ankle wristband Rover and STAT-ON Holter)

  3. Change in Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores

    Time frame: after each 7 day block

    Change in MDS-UPDRS III score. The scale consists of 18 items that are each scored 0 to 3, making the total score out of 72 points, with higher scores indicating higher impairment.

  4. Change in Stride Length

    Time frame: 14 day long-term testing period

    Change in stride length measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride length measured in meters.

  5. Change in Stride Time

    Time frame: 14 day long-term testing period

    Change in stride time measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride time measured in seconds.

  6. Change in Double Support Time

    Time frame: 14 day long-term testing period

    Change in stride time measured by Rover (a gait measurement device). Each gait cycle consists of two phases, where both feet are in contact with the ground, called Double Support. Double support time will be measured in seconds (i.e. amount of time both feet are in contact with the ground).

  7. Change in number of freezes

    Time frame: 14 day long-term testing period

    Change in number of freezes measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).

  8. Change in number of falls

    Time frame: 14 day long-term testing period

    Change in number of falls measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).

  9. Change in Activities-Specific Balance Confidence (ABC) Scale

    Time frame: once per day during 14 day long-term testing period

    Change in ABC Scale, which collects measures of confidence in performing various ambulatory activities without falling or experiencing a sense of unsteadiness. The score range is 0-100 with higher scores indicating higher levels of physical functioning.

Secondary outcomes

  1. Change in Montreal Cognitive Assessment (MoCA) scores

    Time frame: after each 7 day block

    Change in MoCA score. The scale consists of 30 1-point questions testing short term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, and orientation to time and place, with scores lower than 26 indicating possible cognitive impairment.

  2. Changes in Parkinson's Disease (PD) Symptoms Questionnaire

    Time frame: once per day during 14 day long-term testing period

    Changes in responses to a questionnaire that collects information about PD symptoms, balance, walking, falls, and freezing of gait.

Sponsors and collaborators

Lead sponsor

Doris Wang, MD, PhD

Other

Collaborators

  • Burroughs Wellcome
  • Michael J. Fox Foundation for Parkinson's Research

Registry information

Official study title

Movement State-Dependent Adaptive Deep Brain Stimulation for Parkinson's Disease

Important dates

Study start
2026
Primary completion
2026
Study completion
2030
First posted
Feb 20, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.